2023
Booster vaccination protection against SARS-CoV-2 infections in young adults during an Omicron BA.1-predominant period: A retrospective cohort study
Wan J, Cazer C, Clarkberg M, Henderson S, Lee S, Meredith G, Osman M, Shmoys D, Frazier P. Booster vaccination protection against SARS-CoV-2 infections in young adults during an Omicron BA.1-predominant period: A retrospective cohort study. PLOS Medicine 2023, 20: e1004153. PMID: 36626376, PMCID: PMC9876273, DOI: 10.1371/journal.pmed.1004153.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 infectionInitial vaccination seriesPositive SARS-CoV-2 PCR testSARS-CoV-2 PCR testVaccination seriesBooster doseBooster vaccinationCohort studyStudy periodYoung adultsAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionSyndrome coronavirus 2 infectionSevere coronavirus disease 2019Polymerase chain reaction testingCoronavirus 2 infectionRetrospective cohort studyPCR testMultivariable Poisson regressionSARS-CoV-2 variantsStatistical analysis planCoronavirus disease 2019Active surveillance approachSARS-CoV-2World Health OrganizationAntimicrobial resistance among canine enterococci in the northeastern United States, 2007–2020
Osman M, Altier C, Cazer C. Antimicrobial resistance among canine enterococci in the northeastern United States, 2007–2020. Frontiers In Microbiology 2023, 13: 1025242. PMID: 36687655, PMCID: PMC9849698, DOI: 10.3389/fmicb.2022.1025242.Peer-Reviewed Original ResearchAntimicrobial resistanceCanine populationMultidrug resistanceStudy periodEmpirical antimicrobial treatmentMultivariable logistic regressionAntimicrobial susceptibility patternsRetrospective study designQuality of careMultidrug-resistant bacteriaMinimum inhibitory concentrationEnterococcal infectionsClinical dataSusceptibility patternsPrescribing decisionsClinical enterococciSurveillance studyAntimicrobial treatmentLogistic regressionHealth concernStudy designDiagnostic centersVancomycin resistanceAnimal Health Diagnostic CenterInhibitory concentration
2022
The impact of vaccination on the burden of invasive pneumococcal disease from a nationwide surveillance program in Lebanon: an unexpected increase in mortality driven by non-vaccine serotypes
Reslan L, Youssef N, Boutros C, Assaf-Casals A, Fayad D, Khafaja S, Akl F, Finianos M, Rizk A, Shaker R, Zaghlout A, Lteif M, Hafi B, Moumneh M, Feghali R, Ghanem S, Jisr T, Karayakoupoglou G, Naboulsi M, Hamze M, Samad S, Khoury E, Sarraf R, Osman M, Raad E, Amin H, Abadi I, Abdo H, Chedid M, Chamseddine F, Barakat A, Houmani M, Haddad A, Nour G, Mokhbat J, Daoud Z, El-Zaatari M, Sokhn E, Ghosn N, Ammar W, Hamadeh R, Matar G, Araj G, Dbaibo G. The impact of vaccination on the burden of invasive pneumococcal disease from a nationwide surveillance program in Lebanon: an unexpected increase in mortality driven by non-vaccine serotypes. Expert Review Of Vaccines 2022, 21: 1905-1921. PMID: 36342411, DOI: 10.1080/14760584.2022.2143349.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseNon-vaccine typesPneumococcal conjugate vaccinePCV13 eraPneumococcal diseaseBurden of IPDSurveillance programHigher valency vaccinesPost-PCV7 eraRecommendation of vaccinationNon-vaccine serotypesImpact of vaccinationNationwide surveillance programAntimicrobial resistance profilesPCV7 eraPCV7 serotypesConjugate vaccineSerotype distributionUnvaccinated populationAntimicrobial stewardshipMortality rateAge groupsResistance profilesStudy periodSignificant decrease